Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.08 USD
Change Today 0.0001 / 0.12%
Volume 520.0
VODG On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

vitro diagnostics inc (VODG) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/15 - $0.25
52 Week Low
12/22/14 - $0.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VITRO DIAGNOSTICS INC (VODG)

Related News

No related news articles were found.

vitro diagnostics inc (VODG) Related Businessweek News

No Related Businessweek News Found

vitro diagnostics inc (VODG) Details

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research and drug discovery. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products with applications to treatment of various diseases, such as heart disease, stroke, Parkinson’s, and Alzheimer’s diseases. The company also develops and sells ‘Tools for Stem Cell and Drug Development technology’ that offers researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it provides VITROPIN, a purified urinary follicle-stimulating hormone (FSH) preparation; cell line-derived FSH for immortalization of pituitary cells known as gonadotropes that synthesize and secrete FSH and LH; and stem-cell derived FSH to generate new cell lines for FSH. Further, the company offers fluorescent labeled stem cells through various specific labels to enhance utility for various applications in stem cell research. It has a strategic partnership with HemoGenix, Inc. The company was founded in 1986 and is based in Golden, Colorado.

2 Employees
Last Reported Date: 02/13/15
Founded in 1986

vitro diagnostics inc (VODG) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $3.0K
Compensation as of Fiscal Year 2014.

vitro diagnostics inc (VODG) Key Developments

Vitro Diagnostics Launches MSC-Derived Cardiac and Neural Cells

Vitro Diagnostics, Inc. has launched cardiac and neural cells that are differentiated from human mesenchymal stem cells, or MSCs. New products include cardiomyocytes, alpha motor neurons and neural stem cells. Newly developed cardiomyocytes and alpha motor neurons compliment existing stem cell-derived cells for use in cell-based assays of drug toxicity: MSC-derived osteoblasts and chondrocytes. Vitro Biopharma has additional cell types in development including dopaminergic neurons, proximal tubule epithelial cells and podocytes. The latter cells will enable cell-based assays for renal toxicity. These new products provide additional options for in-vitro testing of drug & drug candidate toxicity using human cells. Well-characterized human cells provide a platform for relevant toxicology screening as compared to animal cells. Furthermore, co-culture systems including human hepatocytes extend screening to include drug metabolites as well as the drug or drug candidate itself. Drug metabolite toxicity may not be adequately detected using animal cells & tissues. These advances translate to increased detection of toxicity issues at the preclinical stage of drug development and thus, enhanced efficiency of new drug development.

Vitro Diagnostics, Inc. Announces Resignation of Peter Shuster as Member of the Board of Directors

Effective March 30, 2015, Peter Shuster voluntarily tendered his resignation as a member of the board of directors of Vitro Diagnostics, Inc. The resignation is effective immediately.

Vitro Diagnostics, Inc. announced delayed 10-Q filing

On 03/19/2015, Vitro Diagnostics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VODG:US $0.08 USD 0.0001

VODG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lonza Group AG SFr.128.20 CHF -0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation VODG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VITRO DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at